Citigroup Inc. Cuts Position in Twist Bioscience Corporation $TWST

Citigroup Inc. reduced its position in Twist Bioscience Corporation (NASDAQ:TWST) by 24.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 93,458 shares of the company’s stock after selling 30,231 shares during the quarter. Citigroup Inc. owned approximately 0.15% of Twist Bioscience worth $2,630,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Smartleaf Asset Management LLC raised its holdings in Twist Bioscience by 70.6% in the third quarter. Smartleaf Asset Management LLC now owns 1,068 shares of the company’s stock valued at $29,000 after acquiring an additional 442 shares in the last quarter. Geneos Wealth Management Inc. purchased a new position in Twist Bioscience in the second quarter worth approximately $97,000. CWM LLC grew its holdings in Twist Bioscience by 61.4% during the 3rd quarter. CWM LLC now owns 4,331 shares of the company’s stock worth $122,000 after acquiring an additional 1,648 shares in the last quarter. AXQ Capital LP acquired a new position in Twist Bioscience during the 2nd quarter worth approximately $226,000. Finally, Bayesian Capital Management LP purchased a new stake in shares of Twist Bioscience in the 2nd quarter valued at approximately $253,000.

Analyst Ratings Changes

Several equities analysts have issued reports on TWST shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Twist Bioscience in a report on Monday, December 29th. Barclays boosted their price objective on Twist Bioscience from $39.00 to $50.00 and gave the company an “overweight” rating in a research note on Tuesday, February 3rd. Evercore upped their price target on shares of Twist Bioscience from $42.00 to $52.00 and gave the company an “outperform” rating in a research report on Tuesday, February 3rd. TD Cowen reissued a “buy” rating on shares of Twist Bioscience in a research report on Thursday, January 8th. Finally, Robert W. Baird set a $50.00 target price on Twist Bioscience in a report on Tuesday, February 3rd. Seven research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $45.88.

Twist Bioscience Stock Down 3.5%

TWST opened at $46.94 on Friday. Twist Bioscience Corporation has a 52 week low of $23.30 and a 52 week high of $57.88. The firm has a market cap of $2.88 billion, a P/E ratio of -36.67 and a beta of 2.23. The business’s fifty day simple moving average is $43.61 and its 200 day simple moving average is $34.54. The company has a quick ratio of 3.37, a current ratio of 3.78 and a debt-to-equity ratio of 0.03.

Twist Bioscience (NASDAQ:TWST) last issued its quarterly earnings results on Monday, February 2nd. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.02). Twist Bioscience had a negative net margin of 19.56% and a negative return on equity of 27.16%. The business had revenue of $103.70 million during the quarter, compared to analyst estimates of $100.32 million. The company’s revenue was up 16.9% on a year-over-year basis. As a group, equities research analysts anticipate that Twist Bioscience Corporation will post -2.12 EPS for the current fiscal year.

Insider Activity at Twist Bioscience

In related news, insider Dennis Cho sold 5,000 shares of Twist Bioscience stock in a transaction on Wednesday, February 11th. The stock was sold at an average price of $49.93, for a total value of $249,650.00. Following the transaction, the insider owned 138,581 shares in the company, valued at approximately $6,919,349.33. This trade represents a 3.48% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Adam Laponis sold 7,000 shares of the firm’s stock in a transaction dated Thursday, February 12th. The stock was sold at an average price of $50.00, for a total value of $350,000.00. Following the completion of the transaction, the chief financial officer owned 130,031 shares in the company, valued at approximately $6,501,550. This trade represents a 5.11% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 36,609 shares of company stock worth $1,665,151. Corporate insiders own 3.08% of the company’s stock.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.